INFO:

FINALLY APPROVED for RSV! Nirsevimab is a human monoclonal antibody that is approved as a passive immunization treatment for respiratory syncytial virus (RSV) infection in infants. RSV is a common respiratory virus that can cause severe lower respiratory tract infections in young children, especially those with underlying health conditions or premature infants. Nirsevimab works by binding to a specific protein on the surface of the RSV virus, preventing it from infecting cells in the respiratory tract. It is administered as an intramuscular injection and has a long half-life, providing protection against RSV for several months. Clinical trials have shown that nirsevimab can reduce the incidence of RSV lower respiratory tract infections. The drug is now FDA approved and has the potential to be an important preventive measure against RSV infection, particularly in high-risk populations. Has your hospital or clinic starting talking about getting this? Questions? SHARE your excitement